Abstract: Objective To observe the clinical efficacy and safety of cellular immunotherapy combined with metronomic chemotherapy in the treatment of advanced triple negative breast cancer. Methods A total of 59 patients with advanced metastatic triple negative breast cancer were divided into two groups: an observation group (n=30) which was provided with cellular immunotherapy combined with metronomic chemotherapy (capetabine+cyclophosphamidum) and a control group (n=29) which received metronomic chemotherapy alone. Results The observation group produced a higher disease control rate than the control group, without statistical differences (P>0.05). The incidences of hands-feet syndrome, gastrointestinal reaction and myelosuppression were lower in the observation group than that of the control group, where statistical difference was found as to the incidences of gastrointestinal reaction and myelosuppression between the two groups (P＜0.05). For the observation group, the ratios of CD3+, CD4+/CD8+ and NKT were remarkably different after treatment compared with those before treatment (P＜0.05). Conclusions Cellular immunotherapy combined with metronomic chemotherapy is effective to treat advanced triple negative breast cancer, with low toxicity and good tolerance.